CN Patent

CN113354699B — 瑞德西韦的中间体及其制备方法

Assigned to Suzhou Wangshan Wangshui Biopharmaceutical Co ltd · Expires 2023-07-18 · 3y expired

What this patent protects

本发明提供了瑞德西韦(Remdesivir)的中间体及其制备方法。所述制备方法具有成本低、收率高、产品纯度好等优点，可实现瑞德西韦的高效合成。各式中，R 1 、R 2 、R 3 、R 4 、R 5 、R 8 、PG和X如说明书所定义。

USPTO Abstract

本发明提供了瑞德西韦(Remdesivir)的中间体及其制备方法。所述制备方法具有成本低、收率高、产品纯度好等优点，可实现瑞德西韦的高效合成。各式中，R 1 、R 2 、R 3 、R 4 、R 5 、R 8 、PG和X如说明书所定义。

Drugs covered by this patent

Patent Metadata

Patent number
CN113354699B
Jurisdiction
CN
Classification
—
Expires
2023-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Wangshan Wangshui Biopharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.